Short Interest In Revance Therapeutics Falls 12.8%

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 457,081 share decrease in total short interest for Revance Therapeutics Inc (RVNC), to 3,107,399, a decrease of 12.82% since 10/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for RVNC at the 11/15/2017 settlement increased to 165,356, as compared to 115,415 at the 10/31/2017 report. That brought "days to cover" down to 18.79, a 39.15% decrease from the 30.88 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for RVNC at previous short interest release dates:

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

Loading+chart++2017+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where RVNC had been shorted as a hedge.

The chart below shows the one year performance of RVNC shares, versus its 200 day moving average. Looking at this chart, RVNC's low point in its 52 week range is $15.85 per share, with $28.75 as the 52 week high point — that compares with a last trade of $26.00.

Revance Therapeutics Inc Chart

More from Stocks

Dow Ends Lower as Oil Spikes, Washington Turmoil Continues; Tech Gains

Dow Ends Lower as Oil Spikes, Washington Turmoil Continues; Tech Gains

James Cramer: The Two Most Hated Words on Wall Street

James Cramer: The Two Most Hated Words on Wall Street

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

Amazon Could Become the Next Big Player in Autonomous Driving

Amazon Could Become the Next Big Player in Autonomous Driving